Resistance mechanisms against osimertinib in lung adenocarcinoma cells with EGFR-activating mutation

被引：0

作者：

Nishihara, Shigetoshi ^{[1
,2
]}

Yamaoka, Toshimitsu ^{[1
,3
]}

Hasebe, Yuki ^{[1
]}

Ishikawa, Fumihiro ^{[4
]}

Kusumoto, Sojiro ^{[3
]}

Ohmori, Tohru ^{[3
]}

Sagara, Hironori ^{[3
]}

Yoshida, Hitoshi ^{[2
]}

Tsurutani, Junjii ^{[1
]}

机构：

[1] Showa Univ, Adv Canc Trans Res Inst, Tokyo, Japan

[2] Showa Univ, Div Gastroenterol, Dept Med, Med Sch, Tokyo, Japan

[3] Showa Univ, Div Allergol & Respi Med, Dept Med, Med Sch, Tokyo, Japan

[4] Showa Univ, Ctr Biotechnol, Tokyo, Japan

来源：

CANCER SCIENCE | 2023年 / 114卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-2365

引用

页码：1494 / 1494

页数：1

共 50 条

[31] Differential parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with EGFR-activating mutations
Walsh, Alice M.
Lazzara, Matthew J.
INTEGRATIVE BIOLOGY, 2014, 6 (03) : 312 - 323
[32] Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation
La Monica, Silvia
Madeddu, Denise
Tiseo, Marcello
Vivo, Valentina
Galetti, Maricla
Cretella, Daniele
Bonelli, Mara
Fumarola, Claudia
Cavazzoni, Andrea
Falco, Angela
Gervasi, Andrea
Lagrasta, Costanza Annamaria
Naldi, Nadia
Barocelli, Elisabetta
Ardizzoni, Andrea
Quaini, Federico
Petronini, Pier Giorgio
Alfieri, Roberta
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : 1051 - 1063
[33] Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
Gao, Xuejuan
Zhao, Yanfeng
Bao, Yi
Yin, Wei
Liu, Liyu
Liu, Ruchuan
Yu, Zhengquan
Zhou, Xiao
Shuai, Jianwei
CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9621 - 9630
[34] Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Yamaoka, Toshimitsu
Ohmori, Tohru
Ohba, Motoi
Arata, Satoru
Kishino, Yasunari
Murata, Yasunori
Kusumoto, Sojiro
Ishida, Hiroo
Shirai, Takao
Hirose, Takashi
Ohnishi, Tsukasa
Sasaki, Yasutsuna
MOLECULAR CANCER THERAPEUTICS, 2016, 15 (12) : 3040 - 3054
[35] EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib
Ma, Lei
Chen, Rui
Wang, Fang
Ma, Li-Li
Yuan, Ming-Ming
Chen, Rong-Rong
Liu, Jiang
ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (09)
[36] Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
Oztan, A.
Fischer, S.
Schrock, A. B.
Erlich, R. L.
Lovly, C. M.
Stephens, P. J.
Ross, J. S.
Miller, V.
Ali, S. M.
Ou, S. -H. I.
Raez, L. E.
LUNG CANCER, 2017, 111 : 84 - 87
[37] Mechanism of resistance to third-generation EGFR-TKI, osimertinib, in lung adenocarcinoma PC-9 cells
Yamaoka, Toshimitsu
Kishino, Yasunari
Kusumoto, Sojiro
Ando, Koichi
Ohmori, Tohru
Sagara, Hironori
Tsurutani, Junji
CANCER SCIENCE, 2022, 113 : 1633 - 1633
[38] DDX3X Induces Primary EGFR-TKI Resistance Based on Intratumor Heterogeneity in Lung Cancer Cells Harboring EGFR-Activating Mutations
Nozaki, Koichiro
Kagamu, Hiroshi
Shoji, Satoshi
Igarashi, Natsue
Ohtsubo, Aya
Okajima, Masaaki
Miura, Satoru
Watanabe, Satoshi
Yoshizawa, Hirohisa
Narita, Ichiei
PLOS ONE, 2014, 9 (10):
[39] Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
Della Corte, Carminia Maria
Malapelle, Umberto
Vigliar, Elena
Pepe, Francesco
Troncone, Giancarlo
Ciaramella, Vincenza
Troiani, Teresa
Martinelli, Erika
Belli, Valentina
Ciardiello, Fortunato
Morgillo, Floriana
ONCOTARGET, 2017, 8 (14) : 23020 - 23032
[40] JAK2/STAT3 induces erlotinib-resistance in lung cancer cells harboring EGFR-activating mutations
Harada, Daijiro
Harada, Daijiro
Takigawa, Nagio
Ohashi, Kadoaki
Ichihara, Eiki
Kubo, Toshio
Takeda, Hiromasa
Kashihara, Hiromi
Hotta, Katsuyuki
Tanimoto, Mitsune
Kiura, Katsuyuki
CANCER RESEARCH, 2011, 71

← 1 2 3 4 5 →